Narayana Hrudaya Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Q3 is seasonally weak due to festivals (Durga Puja, Diwali, Christmas), so current quarter growth may be muted; patients often postpone elective procedures to Q4.
- The company expects to continue growing at a high single-digit rate in revenue without further investments by improving throughput and operational efficiencies.
- Capacity expansions via brownfield (Bangalore, Kolkata) and greenfield projects will enable higher growth beyond existing bed capacity in 2-3 years.
- Technology investments aimed at faster discharges, improved coordination, and reduced Average Length of Stay (ALOS) help utilize beds more effectively, boosting volumes and revenue.
- New hospital revenues have shown decent growth, with improving EBITDA margins, indicating ongoing ramp-up.
- NHIC (Narayana Health Integrated Care) is growing healthily but primarily focused on preventative care and may feed referrals to hospitals over time.
- Inflationary and government-related headwinds and seasonal factors may moderate near-term growth, but long-term indicators are positive.
See what Narayana Hrudaya management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- For the remaining capex of approximately INR 450-500 crore this fiscal year, around 50% (~INR 250 crore) may be funded through debt.
- Even with this incremental debt, the net debt-to-EBITDA ratio is expected to remain comfortable at 0.3 to 0.4.
- The company has maintained a healthy cash flow and a strong liquidity profile with net debt of INR 0.86 billion as of September 2023.
- No explicit mention of any immediate or planned equity fundraising was made in the transcript.
- The focus appears to be on funding expansion through a mix of debt and internal accruals without significantly leveraging the balance sheet.
See what Narayana Hrudaya management said on order book — free account, 30 seconds.
Capex plans
Yes- Capital outlay of approx. INR 394 crores incurred till Sep-23; balance amount to be spent in remaining quarters of FY24.
- Full-year CapEx budget around INR 1,000-1,137 crores.
- Remaining CapEx (~INR 450-500 crores) expected to be 50% funded by debt, maintaining comfortable net debt-to-EBITDA ratio (0.3 to 0.4).
- Focus on brownfield and greenfield expansions primarily in Bangalore Health City and Kolkata:
- - Brownfield expansions mainly in flagship hospitals (Bangalore, Kolkata).
- - Land acquisition advanced for Kolkata greenfield project; construction to start next year.
- - Bangalore Health City construction to begin Q4 FY24.
- Plans to add 700+ beds over next 3-4 years.
- Investment in upgrading infrastructure: new floors, ICUs, OTs, diagnostics, labs.
- CapEx may lead to margin dilution initially, with reasonable ramp-up expected due to existing location familiarity (e.g., new Cayman hospital).
Track Narayana Hrudaya — get its next earnings analysis in your feed
Margin guidance
Category 3- The company expects to continue growing with a high single-digit revenue growth from existing assets without any further investments, mainly by increasing throughput and operational efficiencies.
- New investments, including bed additions and capacity expansion (brownfield and greenfield projects in Bangalore and Kolkata), are expected to further boost growth.
- EBITDA margins are expected to remain stable or improve due to higher revenues, cost efficiencies, and better realizations.
- Q3 is seasonally weaker due to festivals, with some elective cases postponed to Q4.
- The tax rate for the current year is expected around 10%, with a return to about 25% effective tax rate in future years.
- Capital expenditures ongoing (approx. INR 1,000 crore planned) will support growth; net debt to EBITDA ratio remains comfortable (0.3-0.4).
- The company is confident in sustaining growth while focusing on value-based care and maintaining fair pricing.
Order book
How does Narayana Hrudaya rank vs peers in Healthcare Services?
Pro featureHow does Narayana Hrudaya rank in Healthcare Services?
Compare Narayana Hrudaya against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Narayana Hrudaya's management said in earlier quarters
Others in Healthcare Services this season
- Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
- Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
- Shalby (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…